An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 673 participants.

Also called NCT03514641

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 673 participants (enrolled count) (from the registry)
Sponsor
  • Theracos Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03514641
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03514641. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-18 (actual); primary completion 2018-11-30 (actual). Results posted on 2021-09-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Bexagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Theracos (class: industry)

Record details

Record id
cardio:ct-nct03514641
Content hash
fbe18c88f398f69e2019c36a00ee381a8bb6ba8e12953ed95b38d96a7877645a